These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 26054694)

  • 1. Rational drug discovery design approaches for treating Parkinson's disease.
    Van der Schyf CJ
    Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.
    Carta AR; Simuni T
    Expert Opin Investig Drugs; 2015 Feb; 24(2):219-27. PubMed ID: 25227476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Olanow CW; Jankovic J
    Mov Disord; 2005; 20 Suppl 11():S3-10. PubMed ID: 15822111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th17 cells: a promising therapeutic target for Parkinson's disease?
    Prots I; Winner B
    Expert Opin Ther Targets; 2019 Apr; 23(4):309-314. PubMed ID: 30871383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
    Youdim MB; Geldenhuys WJ; Van der Schyf CJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S281-91. PubMed ID: 18267251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Insight: new drugs in development for Parkinson's disease.
    Colosimo C; Fabbrini G; Berardelli A
    Nat Clin Pract Neurol; 2006 Nov; 2(11):600-10. PubMed ID: 17057747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The scientific basis for the current treatment of Parkinson's disease.
    Olanow CW
    Annu Rev Med; 2004; 55():41-60. PubMed ID: 14746509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel models for Parkinson's disease and their impact on future drug discovery.
    Trigo-Damas I; Del Rey NL; Blesa J
    Expert Opin Drug Discov; 2018 Mar; 13(3):229-239. PubMed ID: 29363335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the treatment of Parkinson's disease.
    Jankovic J
    Mt Sinai J Med; 2006 Jul; 73(4):682-9. PubMed ID: 16878274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evidence for disease modification in Parkinson's disease.
    Lew MF
    Int J Neurosci; 2011; 121 Suppl 2():18-26. PubMed ID: 22035026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Future drug targets for Parkinson's disease].
    Hirsch EC
    Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.